drugset / Trial / NCT00675623

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

NCT00675623

Phase 3 Completed 598 enrolled Medivation, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Connection Study is a six-month confirmatory Phase 3 study to determine the safety and efficacy of Dimebon in the treatment of mild-to-moderate Alzheimer's disease (AD).

Timeline

Start
2008-05
Primary completion
2009-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 5 mg Oral
Subject Latrepirdine Small molecule 20 mg Oral

Indications